Mesenchymal or EMT CTC, as represented by vimentin expression in this study, have previously been associated with tumour invasiveness, chemoresistance, CTC clustering, stem cell characteristics, and poorer clinical outcomes [29, 30]. This evidence concerns the gene VIM and neoplasm.